The aetiology of minimal @entity99 (mHE) remains unclear. It is generally accepted that hyperammonaemia plays a major role, however there are a multitude of metabolic perturbations present. To determine the contribution of hyperammonaemia to mHE symptom development, ten healthy males (Age:25        5  yrs, BM:76.3        7.1  kg, Height:178.6        4.5  cm, mean        SD) received two 4  h intravenous infusions of either a 2% @entity5819 solution (AMM) or a placebo ( @entity1989 ;0.9% @entity2827 ) using a double blind cross-over design. Sensations of fatigue were measured at baseline, 2 and 4  h using the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) questionnaire. Learning _ memory, motor control and cognition were assessed using Rey's Auditory Verbal Learning Test (AVL), Continuous Compensatory Tracking (COMPTRACK) Task and Inhibitory Control Test (ICT) respectively. Arterialised venous blood samples were collected every hour, and analysed for @entity3265 concentration. There was a significantly higher plasma @entity3265 concentration in the AMM trial than the PLA trial at every time point during the infusion, peaking at 2  h (57        4   mol/L PLA, 225        14   mol/L AMM; p   <   0.05). At 2  h there were significantly higher sensations of general fatigue (Z   =   -2.527, p   =   0.008, 2 tailed) and physical fatigue (Z   =   -2.156, p   =   0.027, 2 tailed), and lower sensations of vigour (Z   =   -2.456, p   =   0.012, 2 tailed) for the AMM trial. There were no significant effects on the performance of the psychological tasks. These results demonstrate that hyperammonaemia in the absence of other complications induces significant sensations of fatigue but does not cause the typically observed performance impairment in individuals with mHE. Supporting the hypothesis for synergism between @entity3265 and other co-factors in mHE.

Absence of neuropsychological impairment in hyperammonaemia in healthy young adults; possible synergism in development of XXXX ( @entity99 ) symptoms?

@entity3265 :: ('MESH:D000641', 'Chemical') :: ['ammonia'] @entity1989 :: ('CHEBI:60159', 'Chemical') :: ['PLA'] @entity5819 :: ('MESH:D000643', 'Chemical') :: ['ammonium chloride'] @entity2827 :: ('MESH:D012965', 'Chemical') :: ['sodium chloride'] @entity99 :: ('MESH:D056486', 'Disease') :: ['hepatic encephalopathy']
@entity99 :: (MESH:D056486,Disease) :: ['hepatic encephalopathy']
